Related Experiment Video
Updated: May 6, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
New drugs for children and adolescents with cancer: the need for novel development pathways
Gilles Vassal1, C Michel Zwaan, David Ashley
1Division of Clinical Research, Institut Gustave Roussy, Paris-Sud University, Paris, France.
Abstract:
Despite major progress in the past 40 years, 20% of children with cancer die from the disease, and 40% of survivors have late adverse effects. Innovative, safe, and effective medicines are needed. Although regulatory initiatives in the past 15 years in the USA and Europe have been introduced, new drug development for children with cancer is insufficient. Children and families face major inequity between countries in terms of access to innovative drugs in development. Hurdles and bottlenecks are well known-eg, small numbers of patients, the complexity of developing targeted agents and their biomarkers for selected patients, limitations of US and EU regulations for paediatric medicines, insufficient return on investment, and the global economic crisis facing drug companies. New drug development pathways could efficiently address the challenges with innovative methods and trial designs, investment in biology and preclinical research, new models of partnership and funding including public-private partnerships and precompetitive research consortia, improved regulatory requirements, initiatives and incentives that better address these needs, and increased collaboration between paediatric oncology cooperative groups worldwide. Increased cooperation between all stakeholders-academia, parents' organisations and advocacy groups, regulatory bodies, pharmaceutical companies, philanthropic organisations, and government-will be essential.
Insights
Innovative cancer drugs for children are lacking, leading to deaths and long-term side effects. New drug development pathways and global collaboration are essential to address these critical needs and improve outcomes for pediatric cancer patients.
Area of Science:
- Pediatric Oncology
- Drug Development
- Cancer Research
Background:
- Despite 40 years of progress, 20% of children with cancer still die, and 40% of survivors experience late adverse effects.
- Current new drug development for pediatric cancer is insufficient, failing to meet the urgent need for innovative, safe, and effective medicines.
- Significant global inequities exist in children's access to innovative cancer drugs currently in development.
Purpose of the Study:
- To highlight the critical need for improved drug development pathways for pediatric cancer.
- To identify existing hurdles and bottlenecks in pediatric cancer drug development.
- To propose solutions and foster collaboration among stakeholders to accelerate the availability of novel therapies for children with cancer.
Main Methods:
- This study is a review and analysis of current challenges and potential solutions in pediatric cancer drug development.
- It examines regulatory, economic, and scientific factors influencing the development of new medicines for children.
- The paper synthesizes information on innovative methods, trial designs, and collaborative models.
Main Results:
- Key challenges include small patient populations, complexity of targeted therapies, regulatory limitations, and insufficient return on investment.
- Existing regulatory initiatives in the US and Europe have not adequately addressed the unique needs of pediatric cancer drug development.
- There is a significant gap in accessing innovative drugs for children globally.
Conclusions:
- New drug development pathways incorporating innovative methods, enhanced preclinical research, and novel funding models are crucial.
- Improved regulatory frameworks, incentives, and increased global collaboration among all stakeholders are essential.
- Addressing these challenges will improve survival rates and reduce long-term adverse effects for children battling cancer.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion